newsletter3

banner-about

suPARnostic® ELISA

The CE/IVD marked suPARnostic® ELISA assay is a full quantifiable method. The suPARnostic® ELISA assay is based on a simplified double monoclonal antibody sandwich ELISA* assay whereby samples and peroxidase-conjugated anti-suPAR are first mixed together and then incubated in anti-suPAR pre-coated micro wells. The recombinant suPAR standards of the kit are calibrated against healthy human blood donor samples. suPAR concentrations are determined as ng/mL plasma.

*For further information on the sandwich ELISA technology please visit Wikipedia    

elisa1elisa2

Clinical Benefits of ELISA suPARnostic®:
• Triaging – Adds to clinical decision making, when selecting patients for admission.
• Predicting Patient Survival – suPARnostic® beats other biomarkers as well as most used clinical scores.

Contact us

virogates logo2
Blokken 45

3460 Birkerød
Denmark

Phone +45 21 13 13 36
Skype: virogates
CVR No.: 25734033
E-mail: info@virogates.com

 in-2  tw-2